Vinik AI, Zhang Q: Adding insulin glargine versus rosiglitazone: health-related quality-of-life impact in type 2 diabetes. Diabetes Care 30:795–800, 2007

In Fig. 1A of the above-listed article, the y-axis should have been labeled “Improvement From Baseline in Total Symptom Score, Value (%).” The correct figure appears below.

Figure 1—

Unadjusted improvement from baseline in total symptom and symptom distress scores. A: Adjusted difference in change from baseline at week 24, 7.59. P = 0.005. B: Adjusted difference in change from baseline at week 24, 1.92. P = 0.03. ▪, insulin glargine; ▒, rosiglitazone.

Figure 1—

Unadjusted improvement from baseline in total symptom and symptom distress scores. A: Adjusted difference in change from baseline at week 24, 7.59. P = 0.005. B: Adjusted difference in change from baseline at week 24, 1.92. P = 0.03. ▪, insulin glargine; ▒, rosiglitazone.

Close modal